APEX AMI: A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (PCI).

Study of:
Experimental study drug, pexelizumab

The primary purpose of this study is to see whether the experimental study drug, pexelizumab, can help lower the number of deaths or complications after someone has a heart attack.

Stroke, heart failure, cardiogenic shock and death will be tracked.

Patients will be randomized (like the flip of a coin) to study drug or placebo. They will receive intravenous (IV) medication prior to their angiogram and then for 24 hours.

Follow-up includes phone calls at 1, 3, 6 months and 1 year.

Approximately 8500 subjects will be enrolled from 350 sites located in 15 countries.

Timothy D. Henry, MD, FACC

Gretchen Peichel, RN

For more information about this study or other research studies at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact Betsy Wilson at 612-863-7065.